During the 16-week dose escalation period, patients were titrated to WEGOVY 2.4 mg injected subcutaneously once weekly or placebo
Lastly, for patients with significant high-end metabolic issues, sleep apnea, heart disease, uncontrolled hypertension, or immobility due to high BMI, GLP-1s alone may not be enough
Aetnas typical PA requirements for Wegovy and Zepbound include: Documented BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea) Evidence of participation in a structured weight management program (diet, exercise, behavioral counseling) for a minimum period often 3 to 6 months Documentation that other weight loss interventions have been attempted Prescriber must be a physician, NP, or PA with appropriate prescribing authority Prior authorization is not a denial it is a documentation requirement
instead, it typically becomes cloudy, yellowed, or develops floating particles
Est indicado para adultos con diabetes mellitus tipo 2 cuando la dieta y el ejercicio por s solos no son suficientes para controlar la glucosa en sangre
